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everal lines of evidence suggest that both cen-
tral serotonin (5-HT) and noradrenaline (NA) dysfunc-
tion may play a role in the pathogenesis or pathophysi-
ology of major depression.
1-5The serotonergic hypothesis
of depression
6 is based on several findings:the ability of
tryptophan depletion to induce depressive symptoms,
higher postmortem 5-HT2A/C receptor binding and
lower postmortem 5-HT1A receptor binding in the
brains of depressed patients, and reduced responsive-
ness of the serotonergic system to neuroendocrine chal-
lenge studies.Various serotonin probes have been pro-
posed as an index of the overall functional status of the
central serotonergic system, but fenfluramine (a 5-HT
releaser/uptake inhibitor) is the most widely used.Both
d-fenfluramine (d-FEN) and the racemate have been
used, but the former is a more specific serotonergic
probe, since it lacks the dopaminergic and noradrener-
gic action of dl-fenfluramine.There have been some
studies of the hormonal response to d-FEN in depressed
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Spatients but the results are inconsistent. Some authors
7
found a decreased prolactin (PRL) response in patients
with major depression compared with normal control
subjects, but others
8 could not replicate this finding.
However,these studies did not address whether a blunt-
ed PRL response correlates with suicidal behavior.A
recent study
9 analyzed a sample of outpatients without
a history of a suicide attempt and did not find a differ-
ence between normal volunteers and depressed patients
in the PRL response to d-FEN.
The original catecholamine depletion hypothesis of
depression has been reformulated as the “noradrener-
gic dysregulation hypothesis,”
10 which emphasizes a pri-
mary subsensitivity or downregulation in nerve terminal
α 2-adrenoreceptors, leading to impaired negative feed-
back on the presynaptic neuron, which, in turn, may
induce a disinhibition of NA output and exaggerated
NA release in response to any activation of the cate-
cholaminergic system. One of the most consistently
reported abnormal findings in depression is a blunted
growth hormone (GH) response to the acute adminis-
tration of clonidine,a partial α 2-adrenoreceptor agonist,
suggesting subsensitive postsynaptic α 2-adrenoreceptors
at the hypothalamic level.Some studies have suggested
that a dysregulation of the noradrenergic system may
lead to increased anxiety in depressive patients.
11,12 It has
also been found that a blunted GH response to cloni-
dine may be a biological correlate of suicidal behavior.
13
The objective of this study was to examine the relation-
ships between central NA and 5-HT function and the
clinical characteristics of a major depressive episode.
Subjects and methods
Subjects
Fifty-three inpatients meeting the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition
(DSM-IV)
14 criteria for a current major depressive
episode (26 males/27 females; age, mean ± SEM,
40.9±1.3 years) formed the patient group.All patients
had been drug-free for a minimum of 15 days, and
washout was supervised in hospital. The severity of
depression was measured with the 17-item Hamilton
rating scale for depression
15 (HAM-D); inclusion in the
study required a baseline HAM-D of 18 or greater
(mean ± SEM:25.0±0.7).Six patients had a single major
depressive episode,37 had a recurrent episode with full
interepisode recovery, and 10 had a recurrent episode
without full interepisode recovery.Thirty-seven patients
had concomitant symptoms of anxiety, with a score
greater than 15 on the Hamilton rating scale for anxiety
(HAM-A).
16
Subjects with clinical evidence of thyroid or other
endocrine diseases, concomitant physical illness, a histo-
ry of alcoholism or other drug abuse,previous treatment
with fluoxetine,lithium salts,carbamazepine,monoamine
oxidase inhibitors (MAOIs), or electroconvulsive thera-
py,and women taking oral contraceptives were excluded.
All subjects were within 15% of their ideal body weight.
Since there is a transient increase in PRL at ovulation,all
females,except for 6 postmenopausal women,were test-
ed outside the periovulatory phase of the menstrual cycle
in order to minimize the influence of the menstrual phase
on PRL secretion.All subjects were on a caffeine-restrict-
ed diet for at least 3 days before testing, and their envi-
ronments were synchronized, with diurnal activity from 
8 AM to 11 PM and nocturnal rest (sleep).This research
was approved by the local ethics committee.
Thirty-two patients had a history of a suicide attempt
(mean ± SD, 2.0±1.1 lifetime suicide attempts) and 21
did not. Patients with a positive suicide history were
then classified as: past suicide attempters (n=13), if the
most recent suicide attempt had not occurred during the
current depressive episode (d-FEN test performed 5 to
86 months after most recent suicide attempt); or recent
suicide attempters (violent:n=7;nonviolent:n=12),if the
suicidal act had occurred during the current depressive
episode,and had triggered their psychiatric hospitaliza-
tion (d-FEN test performed 11 to 37 days after most
recent suicide attempt).The Lethality Rating Scale
17 was
used to measure the degree of medical damage of the
most lethal lifetime suicide attempt. Medical damage is
defined as the danger to life from a suicide attempt.Fol-
lowing Malone et al,
18 we scored no medical damage = 0
and death = 8 (mean ± SD,2.8±1.3).The suicide attempt
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methods were classified as nonviolent (drug overdose)
or violent (cutting beyond a superficial scratch,jumping
from a height,shooting,hanging).
19
Neuroendocrine investigations
On day 1, a clonidine (CLO) test was carried out at 
9 AM,after an overnight fast.A GH assay was performed
at -30, -15, 0, 15, 30, 60, 90, 120, and 150 minutes.The
change in GH after CLO (5 µg/kg orally) was expressed
as the maximum increment above the baseline level
(mean of -30, -15, 0 minutes) (∆ GH). Subjects who had
baseline GH levels >2 ng/mL were excluded.We defined
a blunted ∆ GH as a level ≤ 5 ng/mL.
11
A d-FEN test (45 mg orally) was carried out at 9 AM,on
day 5, after an overnight fast.An assay of PRL was per-
formed at -30, -15, 0, 60, 120, 180, 240, and 300 minutes.
The change in PRL after d-FEN was expressed as the
maximum increment above the level at t0 (∆ PRL),since,
in the morning,PRL concentrations decrease (due to the
normal circadian rhythm).We excluded from the study
all patients with a baseline PRL greater than 20 ng/mL.
We defined a blunted ∆ PRL as a level ≤ 0 ng/mL.
20
Patients were then classified into 4 groups (Table I):
group 1 (n=6; 11%) was defined by blunted ∆ PRLd-FEN
alone; group 2 (n=17; 32%) was defined by blunted
∆ GHCLO alone; group 3 (n=9; 18%) had a combination
of blunted ∆ PRLd-FEN and ∆ GHCLO; group 4 (n=21;
39%) had no abnormality in the d-FEN and CLO tests.
Assays
Blood samples were immediately centrifuged at 1500 g
and 4°C; plasma samples were then stored at -20°C until
assay. Hormonal concentrations were determined by
radioimmunoassay techniques (GH;sensitivity:0.2 ng/mL;
intra-assay and interassay coefficients of variation: 3.7%
and 4.5% [Pharmacia hGH RIA 100,Uppsala,Sweden]),
or immunometric techniques based on enhanced lumi-
nescence (PRL; sensitivity: 1.3 ng/mL; intra-assay and
interassay coefficients of variation:5.5% and 6.0% [Amer-
lite Prolactin Assay,Amersham SA,UK]).
Data analysis
Between-group differences were tested for significance
by analysis of variance (Kruskal-Wallis H test), and,
where the overall effect was significant,by means of the
Mann-Whitney two-tailed test (U test), using Bonfer-
roni’s correction. Correlations between quantitative
variables were estimated using the Spearman rank coef-
ficient (ρ ).Categorical data were analyzed by either the
χ
2 test or Fisher’s exact test.The level of statistical sig-
nificance was set at P=0.05.
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Table I. Clinical characteristics of the 4 groups defined by their responses to d-fenfluramine and clonidine tests (mean ± SEM).
Bl.∆ PRLFEN, indicates blunted peak concentration minus basal prolactin concentration (d-fenfluramine [d-FEN] test); Bl.∆ GHCLO,
blunted peak concentration minus basal growth hormone concentration (clonidine [CLO] test); HAM-D17, Hamilton Rating Scale
for Depression, 17-item version; HAM-A, Hamilton Rating Scale for Anxiety; lethality: medical damage caused by the most
severe lifetime suicide attempt; *with χ
2 test; NS, not significant.
Group 1
(n=6;11%)
Bl.∆ PRLFEN
35.8±2.3
4/2
75.3±6.0
0.0±0.0
7.3±1.3
25.3±1.9
15.2±3.0
5.8±2.7
5.2±3.5
2.0±0.6
3.3±0.7
Group 2
(n=17;32%)
Bl.∆ GHCLO
42.8 ± 2.2
9/8
68.1±2.8
8.4±2.5
0.9±0.4
26.3±1.6
23.1±1.8
3.7±0.6
10.0±2.8
0.5±0.2
0.6±0.3
Group 3
(n=9;18%)
Bl.∆ PRLFEN∆ GHCLO
46.2±1.9
2/7
67.7±1.8
0.0±0.0
0.9±0.3
25.3±1.5
21.3±2.6
9.3±2.8
16.8±2.2
2.1±0.4
3.1±0.4
Group 4
(n=21;39%)
No abnormality
38.5±2.3
11/10
65.1±2.9
9.6±3.1
10.5±1.6
23.6±1.0
17.7±1.5
2.7±0.3
9.5±2.0 
1.1±0.2
1.8±0.4
ANOVA
(H test)
P values
0.07
NS*
NS
0.00001
0.00001
NS
0.06
0.01
0.04
0.004
0.001
Age (years)
Sex (M/F)
Weight (kg)
∆ PRLd-FEN (ng/mL)
∆ GHCLO (ng/mL)
HAM-D17
HAM-A
Number of episodes
Total duration (years)
No. of suicide attempts
Lethality302
The form of multivariate analysis chosen was a factorial
correspondence analysis (FCA).
21-23This analysis is based
on categorical data recorded in a contingency table, ie,
clinical variables (column) in each group defined by neu-
roendocrine tests (row). FCA may be regarded infor-
mally as a form of principal component analysis in which
the contribution of each element in a row (or column) of
the contingency table is weighted according to the con-
tribution of the row (or column) to the total variance of
the table.This form of analysis is thus particularly suited
to summarizing the clinical characteristics of predefined
biological groups, since variables contributing relatively
little to the total variance will receive relatively low
weighting.The following principles
24 were applied for the
interpretation of the FCA results: (1) determination of
the number of necessary axes—the contribution to the
total inertia made by these axes must be at least 80%;(2)
selection of the most important factors on each axis, ie,
having a high relative contribution to the total inertia
explained by the axis—the sum of these contributions
must reach at least 80% of the inertia explained by the
axis and/or the square of the cosine of the factor loading
on the axis must exceed 0.80; and (3) the coordinates of
these factors on the axes determine their association or
their opposition, ie, whether they are on the same or on
opposing sides of the axis.
Results
As summarized in Table I, gender distribution, weight,
and severity of depression were comparable among the
4 groups defined by their responses to d-FEN and CLO
tests.There was a trend towards higher age and anxiety
scores in group 2 and 3.On the other hand,groups 1 and
3 had higher numbers of suicide attempts than groups 2
and 4.
Relationships between d-FEN and 
CLO test responses and clinical characteristics 
among the depressed patients
The d-FEN and CLO test responses were not correlat-
ed (ρ =0.15; ns), and neither of these tests was correlat-
ed with the severity of depression as evaluated with
total HAM-D scores (Table II). However, ∆ PRLd-FEN
values were negatively correlated with the number of
suicide attempts, medical damage caused by the most
severe lifetime suicide attempt,and number of previous
depressive episodes. It may be noted that the number
of suicide attempts was positively correlated with med-
ical damage caused by the most severe lifetime suicide
attempt (ρ =0.91, P<0.00001) but not with the number
of previous depressive episodes (ρ =0.10).
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Table II. Relationships between d-fenfluramine and clonidine test responses and clinical characteristics among 53 DSM-IV drug-free
major depressed inpatients.Expressed as: Spearman rank coefficient (significance level). ∆ PRLd-FEN indicates peak concentration
minus basal prolactin concentration (d-fenfluramine [d-FEN] test); ∆ GHCLO, peak concentration minus basal growth hormone
concentration (clonidine [CLO] test); HAM-D17, Hamilton Rating Scale for Depression, 17-item version; HAM-A, Hamilton Rat-
ing Scale for Anxiety; lethality, medical damage caused by the most severe lifetime suicide attempt; NS, not significant.
PRL response to d-FEN
(∆ PRLd-FEN)
ρ =0.03 (NS)
ρ =0.08 (NS)
ρ =-0.06 (NS)
ρ =-0.50 (P=0.0003)
ρ =-0.57 (P<0.00001)
ρ =-0.33 (P=0.02)
GH response to CLO
(∆ GHCLO)
ρ =-0.39 (P=0.005)
ρ =-0.39 (P=0.005)
ρ =-0.19 (NS)
ρ =0.13 (NS)
ρ =0.07 (NS)
ρ =-0.35 (P=0.01)
Age
HAM-A scores
HAM-D17 scores
Number of suicide attempts
Lethality
Number of previous episodes303
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With regard to the clonidine test, ∆ GHCLO values were
negatively correlated with HAM-A,number of previous
depressive episodes, and age.The number of previous
depressive episodes was positively correlated with age
(ρ =0.49;P=0.0006) and total duration of illness (ρ =0.75;
P<0.00001);age was correlated with total duration of ill-
ness (ρ =0.59;P<0.00001).
Factorial correspondence analysis (FCA)
This analysis, performed on clinical data, provides a
graphical representation, shown in Figure 1.The repre-
sentation of the analysis as a scatterplot of each feature
allows the interpretation of relative positions in terms of
similarity or association between the categories. In the
present study,such an analysis was used to describe the
characteristics of the four groups defined by the
responses to the d-FEN and CLO tests (Table III).The
distribution of certain clinical characteristics was signif-
icantly different across the groups when each character-
istic was considered separately: age and total duration
of the illness were higher in group 3 (χ
2=7.68, df=3,
P=0.05; χ
2=15.50, df=3, P=0.016, respectively); patients
in groups 1 and 3 more often had a history of suicide
attempt (χ
2=14.06, df=3, P<0.003); the medical damage
caused by the most severe lifetime suicide attempt was
higher in group 1 (χ
2=14.50, df=3, P=0.02); patients in
group 2 had more often severe anxiety (χ
2=19.08, df=6,
P=0.004).
The graphical presentation of the FCA was made using
two axes: the first axis accounted for 51% and the sec-
ond for 30% of the total variance.The first axis con-
trasted group 2 (contributing 44%) with group 3 (con-
tributing 42%), and the second axis contrasted group 1
(contributing 74%) with group 3 (contributing 24%).
Therefore, these three groups were well separated on
the FCA representation and their clinical characteristics
could be defined.
The patients in group 1 (ie, with serotonin dysfunc-
tion—as measured by the d-FEN test—and without
noradrenergic dysfunction) were characterized by vio-
lent suicidal behavior,a high degree of medical damage,
and mild anxiety.The patients in group 2 (ie,with nora-
drenergic dysfunction—as measured by the CLO test—
and without serotonergic dysfunction) were character-
ized by an absence of a history of a suicide attempt and
severe anxiety.
The patients in group 3 (ie,with combined serotonin and
noradrenergic dysfunction) were characterized by a his-
tory of suicide attempts,total duration of the illness over
10 years, age over 40 years, and more than 3 previous
hospitalizations.The patients in group 4 (ie, without
Figure 1. Representation of the
four biological groups, defined
by d-fenfluramine and clonidine
test status, by means of a facto-
rial correspondence analysis (see
text for details). GH, growth
hormone; N Hosp, number of
hospitalizations; PRL, prolactin.
Group 1
Group 3
(blunted ∆ PRL and ∆ GH)
Group 4
(no abnormality)
(blunted ∆ PRL alone)
Moderate 
anxiety
Female
N Hosp >3
History of suicide attempt
Recent violent
suicide attempt
Serious medical
damage
Total duration of illness
>10 years
Recent nonviolent
suicide attempt
Age >40 years
Mild anxiety
51%
30%
Bipolar
Group 2
(blunted ∆ GH alone)
Duration <10 years N Hosp <3
Age <40 years
Male
Severe
anxiety No history
of suicide
attempts
Duration <1 year
Age >30 years
moderate depression
Lethality
Psychotic features304
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Table III. Clinical characteristics of groups defined by d-fenfluramine and clonidine test status.
* The suicidal act had occurred during the current depressive episoder and had triggered the psychiatric hospitalization.
† Medical damage caused by the most severe lifetime suicide attempt.
Group 1
(n=6; 11%)
Bl.∆ PRLd-FEN
4 (67%)
2 (33%)
4 (67%)
2 (33%)
2 (33%)
2 (33%)
2 (33%)
3 (50%)
3 (50%)
3 (50%)
2 (33%)
1 (17%)
5 (83%)
1 (17%)
2 (33%)
3 (50%)
1 (17%)
0 (0%)
5 (100%)
0 (0%)
5 (83%)
1 (17%)
3 (50%)
1 (17%)
2 (33%)
Group 2
(n=17; 32%)
Bl.∆ GHCLO
9 (53%)
8 (47%)
10 (59%)
7 (41%)
7 (41%)
7 (41%)
3 (18%)
10 (59%)
7 (41%)
3 (18%)
10 (59%)
4 (23%)
5 (29%)
12 (71%)
16 (94%)
1 (6%)
0 (0%)
4 (80%)
1 (20%)
2 (12%)
10 (59%)
5 (29%)
0 (0%)
2 (12%)
15 (88%)
Group 3
(n=9; 18%)
Bl.∆ PRL and ∆ GH
2 (22%)
7 (78%)
1 (11%)
8 (89%)
4 (44%)
4 (44%)
1 (11%)
2 (22%)
7 (78%)
0 (0%)
1 (11%)
8 (89%)
9 (100%)
0 (0%)
4 (44%)
1 (11%)
4 (44%)
5 (56%)
4 (44%)
0 (0%)
7 (78%)
2 (22%)
1 (11%)
5 (56%)
3 (33%)
Group 4
(n=21; 39%)
No abnormality
11 (52%)
10 (48%)
13 (62%)
8 (38%)
10 (48%)
10 (48%)
1 (4%)
12 (57%)
7 (33%)
4 (19%)
8 (38%)
7 (33%)
13 (62%)
8 (38%)
12 (57%)
2 (10%)
7 (33%)
12 (92%)
1 (8%)
4 (19%)
15 (71%)
2 (10%)
6 (29%)
8 (38%)
7 (33%)
Gender
Men
Women
Age
≤ 40 years
>40 years
Severity of depression
Moderate
Severe
With psychotic features
No. of hospitalizations
<3
≥ 3
Total duration of disorder 
≤ 1 year
Between 1 and 10 years
>10 years
History of suicide attempt
Yes
No
Recent suicide attempt*
No
Violent
Nonviolent
Lethality†
<3
≥ 3
Course
Single episode
Recurrent
Bipolar
Anxiety
Mild
Moderate
SevereSerotonergic and noradrenergic function in depression - Duval et al Dialogues in Clinical Neuroscience - Vol 2 . No.3 . 2000
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abnormality of the d-FEN and CLO tests) had no spe-
cific clinical profile.
However, neither serotonin dysfunction nor noradren-
ergic dysfunction was associated, in our sample, with
core depressive symptoms, such as depressed mood,
feelings of guilt, loss of interest, psychomotor retarda-
tion,or with severity of depressive symptoms.
Discussion
Our study clearly shows that serotonergic dysfunction,
as measured by the d-FEN test,is associated with suici-
dal behavior, and that noradrenergic dysfunction, as
measured by the CLO test, is mainly associated with
severe anxiety in depressed patients.These results are
in accordance with previous studies.
9,11,12,18,19
Prolactin response to d-fenfluramine and suicidal
behavior
It is known that d-FEN activates 5-HT transmission in
the brain by stimulating the release of 5-HT and by
inhibiting the uptake of this amine at the presynaptic
level, leading to an increase in the concentration of 
5-HT in the synaptic cleft.
25 However,at the postsynap-
tic level, the exact process by which d-FEN stimulates
PRL release remains to be clarified. It has been sug-
gested that 5-HT1A receptors are involved in PRL secre-
tion,
26 whilst some authors have shown a role for the 
5-HT2A and/or 5-HT2C receptors,
27,28 and little or no role
for the 5-HT1A
29 and 5-HT3 receptors.
30 Finally, others
suggest that both 5-HT1A receptors and 5-HT2A/2C must
be occupied by endogenous 5-HT in order to stimulate
PRL release.
31 Given this pharmacological background,
a blunted PRL response to d-FEN may be indicative of
a dysfunction of the hypothalamic-pituitary serotoner-
gic system, ie, a reduced serotonergic tone perhaps sec-
ondary to reduced 5-HT presynaptic release, but does
not define which serotonin receptor subtypes, at the
postsynaptic level,are dysregulated.
In our study,we found that patients with a recent violent
suicide attempt—and high degree of medical damage—
have a blunted PRL response to d-FEN,suggesting that
5-HT dysfunction is associated with such suicidal behav-
ior. Moreover, serotonin dysfunction was correlated
with the number of suicide attempts, suggesting that
reduced serotonergic function may be indicative of sus-
ceptibility to suicidal behavior. In addition, there was a
negative correlation between PRL response to d-FEN
and lethality,suggesting that the lower the level of 5-HT
function,the more the depressed patients make suicide
attempts over time and the more lethal they are.On the
other hand, 5-HT dysfunction was not associated with
the core symptoms of depression, which may indicate
that decreased 5-HT function is more closely associated
with suicide than with depression itself.This hypothesis
is supported by a double-blind randomized study
32 that
has shown that paroxetine, a serotonergic antidepres-
sant, reduced suicidal behavior in patients with repeat-
ed suicide attempts but not suffering from major depres-
sion. In addition, our group
33 recently found lower 
d-FEN–induced PRL stimulation in nondepressed
schizophrenic patients with a history of suicide attempts
compared with controls and schizophrenic patients
without a history of suicide attempts.Taken together,
these data suggest that serotonergic dysfunction is asso-
ciated with suicidal behavior independently of nosolog-
ical status.
Growth hormone response to clonidine and anxiety
The blunted GH response to CLO is well documented
in depression.
2,10,34-36 Such a response may be due to
hyporesponsivity of postsynaptic  2-receptors,via hypo-
thalamic growth hormone–releasing hormone (GHRH)
release,
37 linked to an erratic release of norepinephrine.
38
However, a blunted GH response to CLO does not
appear specific to depression, as it has also been
observed in generalized anxiety disorder,
39 panic disor-
der,
40,41 and social phobia.
42 Our finding of a negative cor-
relation between GH response to CLO and HAM-A
scores suggests a link between anxiety and noradrener-
gic dysregulation even in depressed patients.This is fur-
ther confirmed by the FCA results, since patients who
had blunted CLO-induced GH stimulation alone (group
2) were those who exhibited the highest level of anxiety.
On the other hand,the patients of this group 2 were also
characterized by an absence of a history of a suicide
attempt, suggesting that there is no link between nor-
adrenergic dysregulation and suicidal behavior.This
finding seems to contradict a previous report
43 which
suggests that blunted GH response to CLO could be a
biological correlate of suicidal behavior. It should be
noted that these same authors were unable to confirm
this preliminary finding in a subsequent report,
44 con-
cluding that “noradrenergic disturbances,particularly atBasic research
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the level of α 2-adrenergic receptors, seem to play a
minor role in suicidal behavior.”The results of our study
are in agreement with such a conclusion.
Relationship between serotonergic and noradrenergic
dysfunction
In our study, despite the known reciprocal relationship
between the 5-HT and NA systems,
45 we found no cor-
relation between the CLO and d-FEN test responses in
depressed patients.In our sample,the combination of a
blunted PRL response to d-FEN and a blunted GH
response to CLO was observed in about 20% of
patients.These patients were clinically characterized by
a history of suicide attempts and long duration of mood
disorder.
It has been found that abnormalities of adrenergic and
serotonergic responsiveness persist in depressed
patients in remission,
46 suggesting that these abnormal-
ities could be a trait marker of depression. Our results
agree with this hypothesis, since both PRL response to
d-FEN and GH response to CLO are negatively corre-
lated with the number of previous depressive episodes,
suggesting therefore a vulnerability to depression.How-
ever, given the clinical characteristics of patients show-
ing both noradrenergic and serotonergic abnormalities
(ie,group 3),it seems that serotonergic dysfunction may
be more specifically a trait marker of suicidality, while
noradrenergic dysregulation may be a marker of recur-
rence of episodes of affective disorder.
However, there is an effect of age on the CLO-induced
GH response,and this could be a confounding factor in
the interpretation of the CLO test results. In our sam-
ple, the relationship between ∆ GH and age was as
strong as that between ∆ GH and duration of mood dis-
order, and the effect of these two factors could not be
separated. Moreover, the mean age of group 2 (ie, with
blunted GH [CLO] alone) was comparable with that of
group 4 (without d-FEN and CLO test abnormalities)
and that of group 1 (with blunted PRL [d-FEN] alone),
suggesting that the differences in endocrine responses
to the tests could not be explained by differences in age.
Conclusion
The results of our study suggest that specific psy-
chopathological features in depression may be linked to
5-HT and/or NA dysfunction. Future studies should
evaluate whether these findings may be relevant for the
selection of antidepressant strategies.However,the fact
that 40% of major depressed inpatients do not show
abnormalities of NA and/or 5-HT system responsive-
ness,and that NA and/or 5-HT dysfunction are not asso-
ciated with the core of depressive symptoms,support the
view that NA and/or 5-HT dysfunction is less likely to
be the primary cause of mood disorders
47,48 but is more
indicative of failure of compensatory mechanisms
involved in affective homeostasic processes.❑
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Funciones serotoninérgicas y noradrenérgicas
en la depresión: correlaciones clínicas
El presente estudio se orientó hacia la investiga-
ción de las relaciones entre las funciones centra-
les noradrenérgicas (NA) y serotoninérgicas (5-
HT) y las características clínicas del episodio
depresivo mayor de acuerdo con el DSM-IV (Diag-
nostic and Statistical Manual of Mental Disorders,
Fourth Edition). Se midió la respuesta de la hor-
mona del crecimiento (∆ GH) a la clonidina (CLO)
– un agonista noradrenérgico  2 – como un indi-
cador de la función central de NA, y la respuesta
de prolactina (∆ PRL) a d-fenfluramina (d-FEN) –
un inhibidor específico de la liberación/recapta-
ción de 5-HT – como un indicador de la función
central de 5-HT en 53 pacientes depresivos, hos-
pitalizados, sin medicación. De acuerdo con las
respuestas a las pruebas de CLO y d–FEN, los
pacientes se clasificaron en 4 grupos. El grupo 1
(sólo con disminución de ∆ PRLd-FEN [11%]) se
caracterizó por un intento suicida violento
reciente, un alto grado de alteraciones médicas y
ansiedad leve. El grupo 2 (sólo con ∆ GHCLO dismi-
nuida [32%]) se caracterizó por la ausencia de
una historia de intentos suicidas y por ansiedad
severa. El grupo 3 (combinación de ∆ GHCLO y
∆ PRLd-FEN disminuidas [18%]) se caracterizó por
una historia de intentos suicidas, una duración
total de la enfermedad superior a 10 años, una
edad mayor de 40 años y más de 3 hospitaliza-
ciones previas. El grupo 4 (sin anormalidades en
las pruebas [39%]) no tuvo ningún perfil clínico
específico. Estos resultados sugieren que, en la
depresión, las características psicopatológicas
específicas pueden relacionarse con una disfun-
ción 5-HT y/o NA. Sin embargo, nuestros resulta-
dos también sugieren que las disfunciones 5-HT
y/o NA con menor probabilidad constituyen la
causa primaria de los trastornos del ánimo, y ellas
más bien son indicadoras de fallas en los meca-
nismos compensatorios que participan en los pro-
cesos de la homeostasis afectiva.
Les fonctions serotoninergique et
noradrenergique dans la depression :
correlations cliniques
Cette étude a été conduite afin de rechercher
les relations existantes entre les fonctions cen-
trales noradrénergique (NA) et sérotoninergique
(5-HT) et les caractéristiques cliniques d’un épi-
sode dépressif qualifié de majeur d’après le DSM-
IV (Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition). Nous avons mesuré la
réponse de l’hormone de croissance (∆ HG) à la
clonidine (CLO, agoniste NA  2) représentant la
fonction NA centrale et la réponse de la prolac-
tine (∆ PRL) à la d-fenfluramine (d-FEN, un inhi-
biteur spécifique de la recapture 5-HT et un libé-
rateur de 5-HT) représentant la fonction 5-HT
centrale, chez 53 patients hospitalisés pour
dépression et non traités. Ces patients ont été
classés en 4 groupes en fonction de leurs
réponses aux tests CLO et d-FEN. Le groupe 1
(∆ PRLd-FEN émoussée isolée [11%]) était caracté-
risé par une tentative de suicide violente récente,
des lésions corporelles sévères et une anxiété
légère. Le groupe 2 (∆ HGCLO émoussée isolée
[32%]) était caractérisé par l’absence de tenta-
tive de suicide dans les antécédents et une
anxiété s évère. Le groupe 3 (association de
∆ PRLd-FEN et de ∆ HGCLO émoussées [18%]) était
caractérisé par des antécédents plus nombreux
de tentative de suicide, une durée totale de la
maladie supérieure à 10 ans, un âge supérieur à
40 ans et plus de 3 hospitalisations antérieures.
Le groupe 4 (pas d’anomalie [39%]) ne présen-
tait pas de profil clinique particulier. Ces résultats
suggèrent que, dans la dépression, des caracté-
ristiques psychopathologiques spécifiques peu-
vent être liés à une dysfonction de 5-HT et/ou
NA qui témoigne plus probablement d’un échec
de la mise en œuvre des mécanismes compensa-
toires impliqués dans l’homéostasie des processus
affectifs qu’elle n’est la cause primaire des
troubles de l’humeur.Basic research
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